<DOC>
	<DOCNO>NCT02472509</DOCNO>
	<brief_summary>It well establish hemolytic disease predispose patient development pigment gallstone . Gallstones note least 5 % child age 10 year , increase 40-50 % second fifth decade . The co-inheritance Gilbert 's syndrome increase risk cholelithiasis four five-fold . In patient chronic hemolysis , total bile lipid concentration decrease total bilirubin total lipid ratio increase . This suggest conjugate capacity hepatocytes surpass excessive amount bilirubin result hemolysis . Increased bilirubin monoconjugate unconjugated bilirubin precipitate bile form complex inorganic ion , mostly calcium , develop stone . Patients hemolytic disorder also develop biliary sludge , suspension precipitate particulate matter bile disperse viscous , mucin-rich liquid phase . The chemical composition precipitate correlate well composition associate stone sludge often stand harbinger future stone development . There strong data suggest benefit treat cholelithiasis UDCA also prevent gallstone development various high risk scenario . There several propose mechanism positive effect UDCA primary prevention pigment stone . Mucoglycoproteins present significant amount black pigment stone contribute matrix gallstone . UDCA suppress secretion protein decrease level various protein bile . It also suggest increased colonic bile salt may solubilize unconjugated bilirubin may prevent calcium complexing . There publish data present role UDCA prevention treatment cholelithiasis hemolytic disease . The investigator hypothesise UDCA benefit patient hemolytic disorder primary prevention pigment stone , possible resolution biliary sludge existent stone , reduction symptomatic episode cholelithiasis .</brief_summary>
	<brief_title>The Role Ursodeoxycholic Acid Treatment Gallstones Hemolytic Disorders</brief_title>
	<detailed_description>The research protocol extend 12 month , participant attend 3 clinic visit Shaare Zedek Medical Centre ; one study enrollment , one 6 month one 12 month . All patient identify medical record review previous clinical , biochemical sonographic evidence gallstone . Patients undergo baseline abdominal ultrasound ass biliary sludge , gallstone , evidence previous cholecystitis ( eg . Thickened gallbladder wall ) . All patient also blood test liver biochemistry , complete blood count , hemolytic screen fast lipid . Participants commence UDCA 15mg/kg/day ( maximum dose 900mg/day ) 2-3 divided dos 12 month . Patients unable tolerate tablet medication start UDCA syrup dose . Each in-house visit include : 1 . An explicit history take review patient 's note , include review symptom , blood test previous ultrasound , medical condition medication . 2 . Physical examination - include measure splenic size , assess right upper quadrant abdominal tenderness 3 . Blood test 1 . Hemoglobin , WBC 2 . Liver biochemistry : ALT , AST , GGT , ALP ( Alkaline Phosphatase ) , Bilirubin ( conjugate unconjugated ) , Albumin 3 . Hemolytic screen : LDH , haptoglobin , reticulocytes 4 . Fasting lipid : LDL , HDL , Triglycerides Repeat abdominal ultrasound perform 12 month . The US specifically relate follow feature comparison baseline US : 1 . Presence biliary sludge 2 . Presence gallstone : i.Size ii.Number 3 . Presence bile duct dilatation 4 . Presence gall bladder wall thickening</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Gallstones</mesh_term>
	<mesh_term>Cholelithiasis</mesh_term>
	<mesh_term>Cholecystolithiasis</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>1 . Diagnosis hemolytic disorder include spherocytosis , G6PD deficiency , thalassemia sickle cell disease . 2 . Patients cholelithiasis bile sludge . 3 . Age great equal 4 year . 4 . Ability consent participate study follow study procedure . 1 . Previous splenectomy ( complete partial ) 2 . Evidence hemolytic crisis time research enrollment 3 . Patients highly symptomatic gallstone plan surgical intervention 4 . Known allergy intolerance UDCA 5 . Existence concurrent hepatic disease 6 . Any laboratory clinical condition investigator considers clinically significant could impact outcome study safety patient .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Ursodeoxycholic acid ( UDCA )</keyword>
	<keyword>White blood cell ( WBC )</keyword>
	<keyword>Alanine Transaminase ( ALT )</keyword>
	<keyword>Alkaline Phosphatase ( ALP )</keyword>
	<keyword>Aspartate Aminotransferase ( AST )</keyword>
	<keyword>Gamma-Glutamyl Transpeptidase ( GGT )</keyword>
	<keyword>Lactate dehydrogenase ( LDH )</keyword>
	<keyword>Low-Density Lipoprotein ( LDL )</keyword>
	<keyword>High-Density Lipoprotein ( HDL )</keyword>
	<keyword>Glucose-6-phosphate dehydrogenase ( G6PD )</keyword>
	<keyword>Ultrasound ( US )</keyword>
</DOC>